Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP

AXQ Capital LP decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 72.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,619 shares of the biotechnology company’s stock after selling 39,088 shares during the quarter. AXQ Capital LP’s holdings in Sarepta Therapeutics were worth $282,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. State of Michigan Retirement System lifted its holdings in Sarepta Therapeutics by 3.1% in the 2nd quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 700 shares during the last quarter. Arizona State Retirement System lifted its stake in Sarepta Therapeutics by 2.8% during the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 717 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in shares of Sarepta Therapeutics by 6.1% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 728 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the period. Finally, New York Life Investment Management LLC lifted its holdings in shares of Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 966 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue topped Street estimates, showing better-than-expected top-line performance for the quarter despite product-specific weakness. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Management emphasized a solid balance sheet and cash position on the call/press release, which can support R&D and the transition period. Press Release: Q4 and Full-Year 2025 Financial Results
• Positive Sentiment: New longer-term and safety data will be presented at the MDA Clinical & Scientific Congress, offering potential catalysts if data are favorable. MDA Conference Presentation Announcement
• Neutral Sentiment: Full earnings materials and the call transcript/slides are available for investors to review management’s details on costs, cash burn and product strategies. Earnings Slides / Press Release
• Negative Sentiment: Earnings per share missed badly: SRPT reported a loss of $3.58/share vs. consensus around a $0.87 loss, a large downside surprise that pressured the stock. MarketBeat Q4 Summary
• Negative Sentiment: Elevidys sales “tumbled,” driving much of the revenue decline vs. prior year and signaling market-share and demand challenges for Sarepta’s key product. Zacks: Sales Beat but Elevidys Sales Tumble
• Negative Sentiment: Revenue declined ~33% year-over-year, underscoring that the company is in a down cycle and must show steady recovery to restore investor confidence. Yahoo Finance: Compared to Estimates
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon replacement), creating near-term leadership uncertainty during a critical turnaround period. Reuters: CEO to Retire
• Negative Sentiment: Company issued cautious 2026 guidance, signaling recovery will be gradual — investors typically punish biotech names that lower near-term visibility into growth. Yahoo Finance: Guidance and Recovery Path

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, January 27th. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada upped their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $19.00 to $26.00 in a research note on Wednesday, November 5th. Finally, Guggenheim decreased their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $33.84.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $17.45 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $109.50. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.83 billion, a PE ratio of -2.07, a P/E/G ratio of 0.48 and a beta of 0.39. The business’s 50-day moving average price is $20.51 and its two-hundred day moving average price is $20.22.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 49.42% and a negative net margin of 38.34%.The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same quarter last year, the company earned $1.90 earnings per share. The firm’s revenue was down 32.7% compared to the same quarter last year. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.60% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.